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Introduction
Colorectal cancer (CRC) is with an estimated 6600 new cases and almost 2800 deaths a year in Sweden, a large health burden and a suitable target for screening.
1 Screening has shown a relative risk reduction for CRC mortality by 16% with guaiac-based fecal occult blood test (gFOBT). 2 Fecal immunochemical test (FIT) is a quantitative test for detecting blood in stool and is used in population-based screening for CRC, for example, in Italy and Spain. 3, 4 As compared with gFOBT, FIT has a higher sensitivity for detecting advanced adenomas and carcinomas, that is, neoplasia. 5, 6 Most screening programs use one single sample; in Spain and Italy, the cut-off level is 20 μg hemoglobin (Hb)/g that corresponds to a positivity about 4%, whereas in Scotland, the cut-off is 80 μg/g yielding a positivity rate of about 2%. 3, 4, 7 Furthermore, colonic lesions seem to bleed intermittently, and thus, repeated FIT could be of use. 8 Sensitivity increases and specificity decreases for detection of neoplasia with low cut-off level and with multiple samples, and the cut-off level and number of samples used in CRC screening is chosen to meet the available colonoscopy resources. 5, 9 Adenomas are an important finding at colonoscopy as they may progress to CRC, thus reducing CRC risk by adenoma removal. 10 Adenomas with advanced features, such as size >10 mm, highgrade dysplasia or villous growth, and the total number of adenomas, could affect the quantity of bleeding, and hence, adenoma characteristics affect the performance of FIT in adenoma detection. 3, 7 The results regarding accuracy of FIT in detecting leftsided versus right-sided neoplasia have been contradictory, some studies indicating lower sensitivity for proximal lesions versus distal 11, 12 and other equal sensitivity. 9 The prevalence of advanced neoplasia (AN) is higher in men than in women in the average risk population, contributing to gender differences in FIT performance. 13, 14 However, FIT positivity rate also increases by age, and FIT sensitivity is higher in older subjects. 15, 16 Previous studies on gender differences in FIT performance involved participants of heterogeneous age, and evaluations of age-specific screening cohorts are scarce.
The aim of this study was to evaluate FIT in CRC screening with two fecal samples at a cut-off level of ≥10 μg Hb/g to examine Hb level in correlation to CRC, adenoma characteristics, and localization and to evaluate gender differences in FIT performance in a large population-based and well-defined age cohort.
Methods
The study is part of the ongoing CRC screening trial Screening of Swedish Colons (NCT02078804), 17 a population-based randomized controlled study of colonoscopy and FIT in CRC screening. Three cohorts of 60-year-olds from the national population registry are randomly assigned to either screening with direct colonoscopy, FIT, or a control group (non-screening), in total 280 000 subjects. There are no exclusion criteria except previous diagnosis of CRC or having had a procto-colectomy. The primary outcome measure is CRC mortality at 15 years of follow-up. All counties in Sweden participate in the study except Stockholm-Gotland, with an established CRC screening program, and Västernorrland county. Both small rural hospitals with an uptake of 40 000 inhabitants and university hospitals with an uptake of 1.8 million inhabitants are participating in the study.
The present study includes individuals invited to the FIT arm of Screening of Swedish Colons from March 2014 until August 2015 that had FIT samples taken before October 31, 2015, and a diagnostic colonoscopy after a positive FIT before November 30, 2015.
Fecal immunochemical test. The invitees in the FIT arm were asked to send two tests (OC-sensor ® Eiken, Japan) with fecal samples from two consecutive bowel movements. The date of collecting the stool was recorded, and the test tubes were mailed to the study laboratory, stored in 2-6°C, and analyzed according to the instructions by the manufacturer. A positive test was considered when at least one of the two samples was ≥10 μg Hb/g feces, corresponding to 50 ngHb/mL buffer solution. Participants with a positive test were invited to follow-up diagnostic colonoscopy scheduled within 4 weeks, and those with negative tests were referred for repeated testing after 2 years.
Endoscopy. The colonoscopy was performed in one of the 33 participating endoscopy units and carried out by a surgeon, a gastroenterologist, or a trained endoscopy nurse, with a self-reported experience of at least 1000 procedures, a minimum of 100 colonoscopies annually, and a caecal intubation rate of >90%.
At the endoscopy unit, the participant completed a questionnaire regarding medication with acetylsalicylic acid (ASA) or nonsteroidal anti-inflammatory drugs (NSAID), and the weight and height was measured. Colonoscopy quality parameters such as bowel cleaning, caecal intubation, and colonoscopy withdrawal time were electronically registered in the study database. Participants with very large adenomas, CRC, or other finding requiring surgery were referred for surgery, and those with adenomas were followed-up according to the Swedish polyp surveillance program. Additional CT-colonography were performed when necessary, for example, in incomplete colonoscopy due to luminal obstruction.
Colonoscopy findings. The anatomical site in colon and macroscopic size (<5, 5-9, 10-19, or >20 mm) of all findings were registered by the endoscopist before sent to the local pathologist for histopathological diagnosis reported to the study database. Advanced adenoma (AA) was defined as adenomas ≥10 mm, adenomas with high-grade dysplasia or a villous component (villous or tubulovillous growth), or ≥3 tubular adenomas <10 mm. Non-advanced adenoma (non-AA) included ≤2 tubular adenomas <10 mm. AN was defined as AA or CRC. CRC was defined as adenocarcinoma invading muscularis mucosae. Hyperplastic polyps (HP) <10 mm were classified as a normal colonoscopy. Other recorded findings at colonoscopy included diverticular disease, inflammation, hemorrhoids, or angiodysplasia. Participants were categorized according to their most advanced finding. Lesions localized between the caecum to the splenic flexure were classified as proximal and lesions distal of the splenic flexure (from descending colon to the rectum) as distal. Participants with both distal and proximal adenomas (advanced and/or non-advanced) were categorized as "both" on adenoma site, whereas those with only proximal or only distal adenomas were categorized accordingly. All CRC and adenoma findings were verified against the pathology report.
Statistical analysis. To analyze the relationship between the level of Hb and different covariates, univariable and multivariable median regressions were used. The comparison of two different cut-off levels and number of samples, concerning the proportion of detected CRC:s among those who underwent colonoscopy, was analyzed using logistic regression within the generalized estimating equations framework. This was performed by creating two different data sets, one for each of the cut-off levels and number of samples. Because an individual could be included in both data sets, correction of the standard errors is required, which is accounted for in the generalized estimating equations framework. To find potential gender differences regarding the proportion of AN, localization of adenomas/CRC:s, positivity, and positive predictive value (PPV), a test of homogeneity (chi-squared test) was used. All analyses were carried out using STATA (v.13). A P value less than 0.05 was considered as statistically significant.
Cut-off levels of blood for positive test were analyzed at 10, 15, 20, 40 and 80 μg Hb/g and calculated for the first sample, the highest of two samples, the lowest of two samples, and for the mean of two samples. The FIT results were assessed in relation to the colonoscopy findings and adjusted for ASA-medication or NSAID-medication and body mass index (BMI), as BMI is a risk factor for colorectal neoplasia. 18 Fecal immunochemical test positivity was defined as the number of participants with positive test divided by the number of participants with analyzable results. The PPV was defined as the number of participants with AA or CRC divided by the number of FIT positives, and number needed to scope (NNS) were defined as the number of participants with AA or CRC divided by the number of colonoscopies, calculated at each cut-off level, number of samples and for mean of two samples.
The regional ethics committee approved the study, and informed consent was considered when participants sent in FIT samples.
Results
In total 12 383 (5632 male and 6751 female) participants had FIT samples analyzed, and 1209 (54% male and 46% female) participants with positive FIT underwent colonoscopy, which was a complete investigation in 1182. The colonoscopy uptake was 87% (1209 of 1396 FIT positives), and the uptake for a complete colonoscopy was thus 85% (1182 of 1396 FIT positives).
Fecal immunochemical test results ranged from 0 to 20 565 μg/g. Sixty-one participants had the same date on both tests and were excluded from analyses regarding first FIT sample. Four participants had only one valid test and were excluded from analyses regarding mean FIT. Median of the first FIT sample was 15.8 (quartile range 4.4-41.8 μg/g); median for the highest FIT was 30 (quartile range 15.2-75.8 μg/g), and median for the mean of two samples was 18.4 (quartile range 10-46 μg/g).
Caecal intubation rate was 95% (1154/1209), and clean bowel was accomplished in 96% (1162/1209). Colonoscopy withdrawal time was >6 min in 96% (1164/1209). Twenty-seven of 1209 endoscopies were not included in the analyses of histopathological diagnosis as the polyp was not sent for pathology; hence, 1182 remained for further analysis.
In 1182 (631 [53%] male and 551 [47%] female) individuals with positive FIT, colonoscopy detected CRC in 27 (2.3%), AA in 269 (23%), non-AA in 221 (19%), other findings in 439 (37%), and normal colonoscopy in 226 (19%) ( Table 1) . In Table 2 , findings at different cut-off levels and for one and two tests are given.
The median of the first FIT sample was significantly higher for participants with CRC and AA compared with those with non-AA, other findings, or normal colonoscopy (Table 3a , P = 0.002, n = 1121). In multivariable analysis, the first FIT sample (n = 1115) was significantly higher for participants with AA and CRC compared with other subgroups (P = 0.005), adjusted for ASA and NSAID medication, gender, other colonoscopy findings, and BMI (Table 3b) . A sensitivity analysis excluding participants with unclean bowel, caecal withdrawal time <6 min and/or incomplete colonoscopy (other than from a stricturing tumor) rended similar results.
Details of adenoma findings are listed in Table 1 . In univariable analysis of adenoma characteristics (localization, size, grade of dysplasia, villousity, and total number of adenomas), only adenoma size was associated to the median of FIT level, (P = 0.01, Table 4 ). The result was confirmed in a multivariable analysis on adenoma characteristics (n = 449) adjusted for ASA and NSAID medication, gender, BMI, and other findings ( Table 5) . The same sensitivity analysis as above rended similar results.
A cut-off level for a positive test of 10 μg Hb/g in the first sample, highest of two samples, mean of two samples, and lowest of two samples yielded a positivity rate of 7.5%, 11%, 8.5%, and 3.6%, respectively. A cut-off level of 40 μg/g corresponded to a positivity of 1.3-4.6%. Table 2 summarizes the FIT positivity, colonoscopy findings, and PPV for different cut-off levels and number of samples.
If the cut-off level is adjusted from 10 to 40 μg Hb/g for the first sample, highest of two samples, mean of two samples, and lowest of two samples, 6 (24%), 7 (26%), 6 (23%), and 4 (19%) of CRCs and 92 (45%), 129 (44%), 120 (49%), and 64 (47%) of ANs would have been undiagnosed (participants not having had a colonoscopy due to positive test), as illustrated in Figure 1a ,c. The number of participants needing colonoscopy would decrease with 458 (61%), 699 (59%), 556 (63%), and 246 (66%) for one sample testing, highest of two samples, mean of two samples, and lowest of two samples, respectively, when increasing the cut-off level from 10 to 40 μg Hb/g ( Table 2 ). For each cut-off level, detection of CRC and AA increased with mean of two samples and highest of two samples compared with first sample. Varying the cut-off levels and number of samples, first sample at cut-off 20 and 40 μg Hb/g detected CRC in 22 and 19 participants, respectively, as compared with mean of two LGD, low grade dysplasia; non-AA, non-advanced adenoma (≤2 tubular adenomas <10 mm); proximal, caecum to splenic flexure; SSA/P, sessile serrated adenoma or hyperplastic polyp >9 mm. Other findings include diverticulas, inflammation, hemmoroids, or angiodysplasia. † According to the most advanced lesion. 137 (18) 270 (36) 138 (18) FIT ( 107 (18) 196 (34) 98 (17) FIT ( 82 (17) 160 (33) 77 (16) FIT ( 39 (13) 98 (34) 42 (14) FIT ( 18 (10) 61 (35) 24 (14) FIT ( 221 (19) 439 (37) 226 (19) FIT ( 170 (19) 321 (36) 164 (18) FIT ( 133 (18) 258 (34) 134 (18) FIT ( 77 (16) 170 (35) 69 (14) FIT ( 35 (12) 99 (35) 36 (13) FIT ( 167 (19) 308 (35) 166 (19) FIT ( 47 (14) 112 (34) 46 (14) FIT ( 22 (11) 69 (35) 20 (10) FIT ( 62 (17) 124 (33) 51 (14) FIT ( 41 (15) 93 (33) 30 (11) FIT ( 35 (15) 65 (29) 23 (10) FIT ( 
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samples at cut-off 40 and 80 μg Hb/g detecting CRC in 20 and 17, respectively (P = 0.006 and P = 0.003, for proportion of detected CRCs). For each cut-off level, the NNS for CRC was lower for the first sample than for mean of two samples and highest of two samples. Varying the cut-off levels and number of samples, NNS for CRC with first sample at cut-off 20 μg Hb/g, highest of two samples at 40 μg Hb/g, and mean of two samples at 40 μg Hb/g was 22, 24, and 17, respectively.
The PPV for CRC and AA increased with higher cut-off levels. For each cut-off level, PPV for CRC was higher with one sample testing compared with mean of two samples and highest of two samples.
The detection of exclusively proximal AAs is between 2% and 6% at all cut-off levels ( Table 2) .
Of 1182 participants, 551 were women (47%) and 631 were men (53%), and the colonoscopy compliance was 83% and 86%, respectively (Tables 1 and 6 ). A significantly higher proportion of AN was detected in men than in women (n = 180 vs 116, P = 0.003). There was no difference in proportion of proximal lesions (adenomas or CRC), n = 64 versus 56 in men and women, respectively (P = 0.323).
If the same number of AN were to be detected in men and women, the cut-off level for the first sample in women could be lowered from 40 to 20 μg Hb/g, yielding AN = 68 for both gender (Table 6 ). Subsequently, the number of FIT positives and colonoscopies would rise with 121 (35%) and 100 (34%), respectively (with a colonoscopy compliance of 83% in women). The same increase in colonoscopy workload (26-32%) would result from reducing cut-off level in women for the first sample from 80 to 40 μg Hb/g and for mean of two samples from 80 to 40 or from 40 to 20 μg Hb/g. Fecal immunochemical test positivity rate was significantly lower for women than men at all cut-off levels and number of samples. PPV was significantly lower in women for AA but not for CRC for one and two samples at cut-off levels <40 μg Hb/g and for mean of two samples at 80 μg Hb/g (Table 6 ).
Discussion
In our cohort study of CRC screening participants having colonoscopy after a positive FIT, FIT values were significantly higher among participants with CRC and AA compared with other subgroups, adjusted for ASA and NSAID medication and presence of other findings such as hemorrhoids and diverticulas that may also be prone to bleeding. Among participants with adenoma, adenoma size was the only independent variable associated with the amount of blood in the feces, and we found no association with dysplasia, villousity, localization, and number of adenomas. This finding is in line with the previous studies showing that both grade of dysplasia and villous component is related to adenoma size rather than FIT positivity, both in a screening population 3, 7 and patients in a hospital setting. 19 Similar as in our study, Digby et al. did not find an association between adenoma site and blood level ≥80 μg/g in the Scottish screening program. 7 On the other hand, in a study of the Florence screening program, FIT was significantly higher for subjects with left-sided versus rightsided adenomas at blood levels ≥20 μg/g, although only the location of the most advanced adenoma (if multiple) was taken into account. 3 Obesity is a risk factor for adenoma formation and CRC 18, 20 and can also influence the quality of the colonoscopy 21 but was not associated with FIT blood level in our study. Typically, the positivity rate of FIT screening programs is 2-4%, 3, 7 which in our data would correspond to a cut-off of about 40 μg/g. Our study demonstrated that nearly half of ANs and every fourth CRC would remain undetected if cut-off level for a positive test was adjusted from 10 to 40 μg Hb/g. A similar result was seen in a study of 20 000 participants of single sample FIT screening (NS-Plus FIT, Osaka, Japan) in which 23% CRCs would be missed if cut-off level increased from 10 to 40 μg/g. 22 However, a cut-off level of 10 μg Hb/g corresponds to a positivity rate of 7.5-11% depending on the number of samples used, which would imply a considerable workload for endoscopy units.
In terms of CRC detection, our data suggest that screening with a single fecal sample at lower cut-off is more suitable than two samples at higher cut-off, yielding a higher CRC detection and almost equal number of AAs. A French study comparing FIT and gFOBT in screening participants favored two sample testing, although the one sample method was obtained from a random sample of two tests rather than from the first dated sample. 23 In terms of number needed to screen, a randomized study of one or two sample FIT screening in the Netherlands found that at positivity rates between 3.2-6.2% (corresponding to cut-off levels from 25 to 40 μg/g for two tests and from 15 to 40 μg/g for one test), both strategies were equally efficient in detecting AN. 8 Also, over repeated screening rounds, Kapdizic et al. found similar detection rates for one and two sample screening. 24 In 2014, the Dutch screening program increased the cut-off level from 15 to 47 μg/g due to lower PPV (42.1%) and higher attendance (71.3%) and positivity (10.6%) rates than expected, so a careful monitoring of screening program when implemented is important. 25 Our study showed that FIT positivity rates were significantly lower for women than men at all cut-off levels and number of samples, in line with previously published data on one sample FIT testing. 13 One possible explanation for lower blood level in feces in women is that FIT is less sensitive to right-sided, often flat, lesions that are more common in women, 12, 26 but in our data, there was no difference in proximal and distal lesions between gender. Significantly more men than women were detected with AN, reflecting also a higher prevalence in men. 27 As AN is more prevalent in men, PPV is higher for men than women, although the differences at cut-off levels ≥40 μg/g was not statistically significant in our data. In the Barcelona screening program, Auge et al. demonstrated lower PPV for AN in women than men at all ages and cut-off levels ≥20 μg/g. 4 In our study, there was also a tendency toward lower PPV for CRC in women, but there were few cases (n = 27), and differences were not statistically significant. An indication that fecal blood screening performs better in men than in women would be a higher incidence of missed cancers among screened women, but this was not supported by a study on interval cancers from the Italian FIT screening program. 28 In a previous study from the Stockholm-Gotland gFOBT screening program on the other hand, the screening detected cancers were more than twice as many in men as in women (150 vs 69), leading to a higher rate of interval cancers among women. 29 In 2015, the Stockholm program shifted from gFOBT to FIT with different cut-off levels applied to men and women (80 and 40 μg/g, respectively). In our data, the same number of AN could be detected among men and women if cut-off level for women was lowered from, for example, from 40 to 20 or from 80 to 40 μg/g, but this would generate a 30% increase in colonoscopy workload and many colonoscopies without significant findings among participating women.
The strength of our study is the population-based nationwide setting with results generalizable to a larger population as if screening was implemented. There are also limitations of this study, due to the setting. First, the detection rate of proximal adenomas in screening varies by endoscopist, 30 hence could be underdiagnosed in our study involving a large number of clinicians, with different specialty and dedication, performing the colonoscopies after a positive test. Second, there could be an inter-observer variability in the pathological distinction between advanced and non-advanced adenomas and between sessile Of FIT positives, 284 male and 270 female are excluded from the first sample as they have the same date on both tests, and five male and four female are excluded from mean of two samples as they have only one valid test. Of those with AA, 10 men and 2 women are excluded from first sample as they have the same date on both tests, and one woman with AA is excluded from mean of two samples because of only one valid test. *Positivity rates are significantly lower for women at all cut-off levels and number of samples (P < 0.05).
**PPV for AA is significantly lower for women at all cut-off levels <40 μg Hb/g and number of samples, and for 80
μg Hb/g mean of two samples (P < 0.05). Differences in PPV for CRC between men and women are non-significant.
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serrated adenomas and HP, (kappa-value 0.48 for HP between GIpathologists). 31, 32 On the other hand, the detection rate of sessile serrated adenomas (n = 20, 1.7%) in our study was similar to other screening cohorts. 33, 34 At last, there is a possibility of Hb degradation of the first FIT samples in our study, if the sample is, despite thoroughly instructions, stored in high temperature awaiting the second test before sending the test by mail. 35 However, there was an equal number of the first samples and second samples being the highest of two (data not shown), indicating that this problem was limited.
Conclusion
This study of an average-risk population of 60-year-olds in Sweden invited and participating in FIT screening for CRC showed that FIT levels are significantly higher for CRC and advanced adenomas and correlated to adenoma size. Moreover, FIT screening with single sample at lower cut-off level for a positive test detected more CRC than two samples at higher cut-off. AN was more often found in men, but applying different cut-off levels for men and women in order to equalize detection rate would increase colonoscopy workload by 30%.
